Pulse Biosciences (NASDAQ:PLSE) Upgraded at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a report published on Thursday.

Pulse Biosciences Stock Performance

Shares of NASDAQ PLSE opened at $19.63 on Thursday. The company has a 50 day simple moving average of $18.06 and a two-hundred day simple moving average of $16.95. Pulse Biosciences has a 12 month low of $6.59 and a 12 month high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter in the previous year, the firm earned ($0.19) earnings per share.

Insider Buying and Selling

In related news, Director Robert W. Duggan purchased 55,256 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the purchase, the director now directly owns 42,328,717 shares of the company’s stock, valued at $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Burke Thomas Barrett sold 50,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the sale, the chief executive officer now directly owns 63,172 shares of the company’s stock, valued at approximately $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 71.50% of the stock is owned by company insiders.

Institutional Trading of Pulse Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp boosted its position in shares of Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after purchasing an additional 69,696 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Pulse Biosciences by 7.8% in the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock valued at $8,020,000 after acquiring an additional 33,200 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after acquiring an additional 97,565 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Pulse Biosciences by 23.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after acquiring an additional 9,639 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Pulse Biosciences in the 3rd quarter valued at $588,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.